Oramed Pharmaceuticals Inc. (ORMP)
NASDAQ: ORMP · Real-Time Price · USD
2.200
-0.010 (-0.45%)
May 15, 2025, 4:00 PM - Market closed
Company Description
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes.
The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses.
Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
Oramed Pharmaceuticals Inc.
| Country | United States |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Nadav Kidron |
Contact Details
Address: 1185 Avenue of the Americas, Third Floor New York, New York 10036 United States | |
| Phone | 844 967 2633 |
| Website | oramed.com |
Stock Details
| Ticker Symbol | ORMP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001176309 |
| CUSIP Number | 68403P203 |
| ISIN Number | US68403P2039 |
| Employer ID | 98-0376008 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Nadav Kidron Esq. | President, Chief Executive Officer and Executive Chairman |
| Avraham Gabay | Chief Financial Officer, Treasurer and Secretary |
| Dr. Miriam Kidron Ph.D. | Chief Scientific Officer and Director |
| Joshua Hexter | Chief Operating and Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2025 | 10-Q | Quarterly Report |
| Apr 28, 2025 | 8-K | Current Report |
| Mar 27, 2025 | 10-K | Annual Report |
| Mar 3, 2025 | 8-K | Current Report |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 13, 2025 | SCHEDULE 13G/A | Filing |
| Feb 11, 2025 | 8-K | Current Report |
| Jan 22, 2025 | 8-K | Current Report |
| Jan 3, 2025 | 8-K | Current Report |
| Dec 17, 2024 | 8-K | Current Report |